Literature DB >> 32251496

Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function.

Paolo Milani1,2, Marco Basset1,2, Paola Curci3, Andrea Foli1,2, Rita Rizzi3, Mario Nuvolone1,2, Raffaella Guido4, Loreto Gesualdo4, Giorgina Specchia3, Giampaolo Merlini1,2, Giovanni Palladini1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32251496      PMCID： PMC7160273          DOI： 10.1182/bloodadvances.2020001553

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  24 in total

1.  Enlightening light chain deposition disease.

Authors:  Giampaolo Merlini; Giovanni Palladini
Journal:  Blood       Date:  2015-12-24       Impact factor: 22.113

Review 2.  Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.

Authors:  Jean-Paul Fermand; Frank Bridoux; Angela Dispenzieri; Arnaud Jaccard; Robert A Kyle; Nelson Leung; Giampaolo Merlini
Journal:  Blood       Date:  2018-07-16       Impact factor: 22.113

3.  First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.

Authors:  Taimur Sher; Brooke Fenton; Adnan Akhtar; Morie A Gertz
Journal:  Blood       Date:  2016-08-19       Impact factor: 22.113

4.  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

Authors:  Giovanni Palladini; Ute Hegenbart; Paolo Milani; Christoph Kimmich; Andrea Foli; Anthony D Ho; Marta Vidus Rosin; Riccardo Albertini; Remigio Moratti; Giampaolo Merlini; Stefan Schönland
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

5.  AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

Authors:  Tobias Dittrich; Tilmann Bochtler; Christoph Kimmich; Natalia Becker; Anna Jauch; Hartmut Goldschmidt; Anthony D Ho; Ute Hegenbart; Stefan O Schönland
Journal:  Blood       Date:  2017-05-26       Impact factor: 22.113

6.  Marked improvement by high-dose chemotherapy and autologous stem cell transplantation in a case of light chain deposition disease.

Authors:  Keiichi Matsuzaki; Isao Ohsawa; Tomohito Nishitani; Yukihiko Takeda; Hiroyuki Inoshita; Masaya Ishii; Miyuki Takagi; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Nephrol       Date:  2011 Mar-Apr       Impact factor: 3.902

7.  Long-term outcome of autologous stem cell transplantation in light chain deposition disease.

Authors:  Elizabeth C Lorenz; Morie A Gertz; Fernando C Fervenza; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Dennis A Gastineau; Nelson Leung
Journal:  Nephrol Dial Transplant       Date:  2008-01-04       Impact factor: 5.992

Review 8.  How I treat monoclonal gammopathy of renal significance (MGRS).

Authors:  Jean-Paul Fermand; Frank Bridoux; Robert A Kyle; Efstathios Kastritis; Brendan M Weiss; Mark A Cook; Mark T Drayson; Angela Dispenzieri; Nelson Leung
Journal:  Blood       Date:  2013-10-09       Impact factor: 22.113

9.  Renal disease and patient survival in light chain deposition disease.

Authors:  C Pozzi; G B Fogazzi; G Banfi; E H Strom; C Ponticelli; F Locatelli
Journal:  Clin Nephrol       Date:  1995-05       Impact factor: 0.975

10.  Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.

Authors:  S Sidana; N Tandon; A Dispenzieri; M A Gertz; F K Buadi; M Q Lacy; D Dingli; A L Fonder; S R Hayman; M A Hobbs; W I Gonsalves; Y L Hwa; P Kapoor; R A Kyle; N Leung; R S Go; J A Lust; S J Russell; S R Zeldenrust; S V Rajkumar; S K Kumar
Journal:  Leukemia       Date:  2017-09-18       Impact factor: 11.528
View more
  6 in total

Review 1.  Kidney injury and disease in patients with haematological malignancies.

Authors:  Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung
Journal:  Nat Rev Nephrol       Date:  2021-03-30       Impact factor: 28.314

2.  Light chain deposition disease involving kidney and liver in a patient with IgD myeloma.

Authors:  Takafumi Tsushima; Tomo Suzuki; Toshiki Terao; Daisuke Miura; Kentaro Narita; Masami Takeuchi; Akira Shimuzu; Kosei Matsue
Journal:  BMC Nephrol       Date:  2021-01-23       Impact factor: 2.388

3.  A case of light chain deposition disease involving the kidney with a normal serum free kappa/lambda light chain ratio.

Authors:  Suojian Zhang; Haifeng Ni; Qin Xu; Xiaoqin Cai; Haitao Li; Zhiqiang Wei; Juan Cao
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

Review 4.  Treatment of Light Chain Deposition Disease: A Systematic Review.

Authors:  Adeel Masood; Hamid Ehsan; Qamar Iqbal; Ahmed Salman; Hamza Hashmi
Journal:  J Hematol       Date:  2022-08-30

5.  Light Chain Deposition Disease Diagnosed Using Computed Tomography-Guided Kidney Biopsy.

Authors:  Yoshinosuke Shimamura; Yayoi Ogawa; Hideki Takizawa; Toshiaki Hayashi; Yasuo Sakurai
Journal:  Cureus       Date:  2021-05-18

Review 6.  Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management.

Authors:  Camille Cohen; Florent Joly; Audrey Sibille; Vincent Javaugue; Estelle Desport; Jean-Michel Goujon; Guy Touchard; Jean-Paul Fermand; Christophe Sirac; Frank Bridoux
Journal:  Diagnostics (Basel)       Date:  2021-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.